The Newest FDA-Approved Obesity Drug Is Also the Oldest
Novo Nordisk gains FDA approval for Saxenda, which is already approved as an obesity treatment called Victoza.
3 Stocks Poised for Eye-Popping Gains in 2015
Gilead Sciences, Orexigen Therapeutics, and Prothena Corp. are all poised to have a huge 2015. Here's what investors need to know.
3 Biotech Stocks I Don't Want for Christmas
I’d prefer coal in my stocking to these three troubled biotech stocks.